Here’s Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS)
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Marinus Pharmaceuticals Inc. (MRNS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 5,073,913 | $8,930,087 | +33% | 0.28% |
| 2. | Tang Capital Management Kevin C. Tang | 4,700,000 | $8,272,000 | -3% | 0.59% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,264,271 | $2,225,117 | -69% | 0.01% |
| 4. | Ikarian Capital Neil Shahrestani | 706,154 | $1,242,831 | 0.17% | |
| 5. | Lion Point Didric Cederholm | 693,778 | $1,221,049 | -68% | 2.71% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.25 | 100,000 | Officer, Director | 100,000 | 2019-12-13 | Filing | |
| $5.61 | 3,561 | Officer, Director | 116,085 | 2015-11-06 | Filing | |
| $8.00 | 419,744 | Large Shareholder | 2,476,886 | 2014-08-05 | Filing | |
| $8.00 | 12,528 | Large Shareholder, Director | 27,998 | 2014-08-05 | Filing | |
| $8.00 | 13,367 | Large Shareholder, Director | 238,212 | 2014-08-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.13 | 4,657 | 79,773 | 2024-08-05 | Filing | ||
| $1.14 | 3,820 | 67,406 | 2024-08-05 | Filing | ||
| $1.13 | 3,621 | 60,263 | 2024-08-05 | Filing | ||
| $1.13 | 4,828 | 72,725 | 2024-08-05 | Filing | ||
| $1.13 | 12,145 | 298,667 | 2024-08-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,599,278 | $49,994,152 | 0% | |
| 2. | 4,529,997 | $49,241,067 | 0.8% | |
| 3. | 3,833,955 | $41,675,091 | 0.01% | |
| 4. | 2,959,161 | $32,166,081 | 0.02% | |
| 5. | 2,673,231 | $29,058,021 | 0% |
News See All
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2024 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2024 Earnings Call Transcript August 13, 2024Marinus Pharmaceuticals, Inc. misses on earnings expectations.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.74 EPS, expectations were $-0.64. Marinus Pharmaceuticals, Inc.
5 Hyper-Growth Stocks Billionaires Are Loading Up On
This article presents an overview of the 5 Hyper-Growth Stocks Billionaires Are Loading Up On. For a detailed overview of such stocks, read our article, 11 Hyper-Growth Stocks Billionaires Are Loading...
5 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the five most promising long-term stocks according to analysts.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Marinus Pharmaceuticals' Third Quarter 2023 Financial Results and Business Update Call. [Operator Instructions].
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Marinus Pharmaceuticals’ Second Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q1 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Marinus Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2022 Earnings Call Transcript
Operator: Greetings everyone and welcome to the Marinus Pharmaceuticals' Fourth Quarter and Full-Year 2022 Financial Results and Business Update Call.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2022 Earnings Call Transcript
Operator: Ladies and gentlemen, greetings and welcome to the Marinus Pharmaceuticals' Third Quarter 2022 Financial Results and Business Update Call.